{"ticker": {"uuid": "853dab36-168f-42e1-8cab-4353e5652941", "symbol": "NVCT", "name": "Nuvectis Pharma Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data", "summary": "Nuvectis Pharma (NASDAQ: NVCT) has secured worldwide rights outside China for NXP100, a once-daily oral therapy for paroxysmal nocturnal hemoglobinuria (PNH), following a licensing deal with Haisco Pharmaceutical Group. NXP100 showed strong positive Phase 3 data, outperforming th", "url": "https://www.cantechletter.com/newswires/streetwatch-nuvectis-pharma-eyes-9-8-billion-oral-pnh-market-with-late-stage-nxp100-backed-by-strong-positive-phase-3-data/", "source_name": "Cantech Letter", "published_at": "2026-07-14T15:43:45", "published_display": "14 Jul 2026 15:43", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Wire: StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data", "summary": "Nuvectis Pharma (NASDAQ: NVCT) recently acquired worldwide rights outside China for NXP100, a promising once-daily oral therapy for paroxysmal nocturnal hemoglobinuria (PNH), following a licensing deal with Haisco Pharmaceutical Group. This acquisition, supported by strong Phase ", "url": "https://www.finanznachrichten.de/nachrichten-2026-07/69024121-wall-street-wire-streetwatch-nuvectis-pharma-eyes-dollar-9-8-billion-oral-pnh-market-with-late-stage-nxp100-backed-by-strong-positive-phase-3-data-296.htm", "source_name": "FinanzNachrichten.de", "published_at": "2026-07-14T14:42:58", "published_display": "14 Jul 2026 14:42", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How (NVCT) Movements Inform Risk Allocation Models", "summary": "This article analyzes Nuvectis Pharma Inc. (NASDAQ: NVCT) using AI models to provide insights into its market movements and inform risk allocation. It highlights weak near-term sentiment but strong mid and long-term signals, offering three distinct trading strategies tailored to ", "url": "https://news.stocktradersdaily.com/news_release/9/How_NVCT_Movements_Inform_Risk_Allocation_Models_071326083802_1783989482.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-13T20:41:32", "published_display": "13 Jul 2026 20:41", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "The Billion-Dollar Pill: With NXP100, Nuvectis Pharma Just Staked Its Claim in the New Biotech Gold Rush", "summary": "Nuvectis Pharma recently acquired worldwide rights outside China for NXP100, a once-daily pill for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. This acquisition, along with an oncology drug NXP200, signifies the company's shift from a single-drug oncology foc", "url": "https://www.tradingview.com/news/financewire:4bad5ea45094b:0-the-billion-dollar-pill-with-nxp100-nuvectis-pharma-just-staked-its-claim-in-the-new-biotech-gold-rush/", "source_name": "TradingView", "published_at": "2026-07-09T19:11:42", "published_display": "09 Jul 2026 19:11", "sentiment": "positive", "sentiment_pct": 86, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma Inc (NVCT) News, Articles, Events & Latest Updates", "summary": "This article provides recent news and updates for Nuvectis Pharma Inc (NVCT), including analyst ratings and price targets suggesting significant upside potential. It highlights the company's recent earnings beat, increased holdings by Iridian Asset Management, and a stock jump fo", "url": "https://stocktwits.com/symbol/NVCT/news", "source_name": "Stocktwits", "published_at": "2026-07-09T08:11:18", "published_display": "09 Jul 2026 08:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQZkpQM0t1Zkdta2V0d2pleXIxcXlMYlpQQm5oX1VZa3RxcnNmTTM2RDBsVTQwMl9IY3pyUVFlclpLaGxRczlmRWMwN3d3aUxpZnFlbGpmR2ZKX3RzbGZ1MGJNQmd3YVkwMWdBRnc5a1hjRGMxSmdxb3NueXYyX2VTdjFwR2kwdTNkM2ZGMUw4dzFVWGl5Q1VR?oc=5", "source_name": "Market source", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma (Nasdaq:NVCT) - Stock Analysis", "summary": "Nuvectis Pharma (NVCT) is a clinical-stage biopharmaceutical company focused on oncology, currently developing precision medicines NXP900 and NXP800. The company has a market capitalization of US$605.3m, but faces significant risks including revenue less than US$1m, unprofitabili", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nvct/nuvectis-pharma", "source_name": "Simply Wall Street", "published_at": "2026-07-07T19:42:38", "published_display": "07 Jul 2026 19:42", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma Price Target Raised to $33.00/Share From $20.00 by Roth Capital", "summary": "Roth Capital has increased its price target for Nuvectis Pharma (NVCT) to $33.00 per share, up from the previous $20.00. This revision suggests a significantly more optimistic outlook on the company's future stock performance.", "url": "https://www.moomoo.com/news/post/72513900/nuvectis-pharma-price-target-raised-to-33-00-share-from", "source_name": "Moomoo", "published_at": "2026-07-06T18:41:13", "published_display": "06 Jul 2026 18:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roth Capital raises Nuvectis target to $33", "summary": "Roth Capital analyst Jonathan Aschoff maintained a Buy rating on Nuvectis Pharma and increased the price target from $20 to $33. This adjustment follows Nuvectis's announcement of a $100 million public offering of 5,000,000 shares at $20.00 each, with the proceeds intended to adv", "url": "https://scanx.trade/stock-market-news/ipo/nuvectis-pharma-commences-underwritten-public-offering-of-common-stock/44309255", "source_name": "scanx.trade", "published_at": "2026-07-06T16:11:51", "published_display": "06 Jul 2026 16:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma (NVCT) CEO Ron Bentsur buys $250,000 in shares", "summary": "Nuvectis Pharma's Chairman and CEO, Ron Bentsur, purchased 12,500 shares of common stock at $20.00 per share, totaling $250,000. This open-market purchase was part of a public offering announced on June 29, 2026. Following this transaction, Bentsur directly owns 3,688,424 shares ", "url": "https://www.stocktitan.net/sec-filings/NVCT/form-4-nuvectis-pharma-inc-insider-trading-activity-c8daabf9cc9e.html", "source_name": "Stock Titan", "published_at": "2026-07-02T05:40:07", "published_display": "02 Jul 2026 05:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma Announces Major Public Equity Offering", "summary": "Nuvectis Pharma (NVCT) announced a firm-commitment public offering of 5,000,000 common shares at $20.00 each through Cantor Fitzgerald, with an option for underwriters to purchase an additional 750,000 shares. This offering is expected to raise approximately $93 million in net pr", "url": "https://www.theglobeandmail.com/investing/markets/stocks/NVCT-Q/pressreleases/3086810/nuvectis-pharma-announces-major-public-equity-offering/", "source_name": "The Globe and Mail", "published_at": "2026-07-02T05:10:08", "published_display": "02 Jul 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma 10% owner Mosseri buys $916k in shares", "summary": "Marlio Charles Mosseri, a 10% owner of Nuvectis Pharma (NASDAQ:NVCT), acquired 50,000 shares worth $916,000 on June 30, 2026, at an average price of $18.32 per share. This insider purchase follows a significant stock decline and a $100 million public offering at a 30% discount. D", "url": "https://www.investing.com/news/insider-trading-news/nuvectis-pharma-10-owner-mosseri-buys-916k-in-shares-93CH-4771166", "source_name": "Investing.com", "published_at": "2026-07-02T04:40:40", "published_display": "02 Jul 2026 04:40", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Buying: Ron Bentsur Acquires Additional Shares of Nuvectis Pharma Inc (NVCT)", "summary": "Ron Bentsur, Chairman & CEO of Nuvectis Pharma Inc (NVCT), recently purchased 12,500 shares of the company, bringing his total ownership to 3,688,424 shares. This transaction is part of a trend of insider buying at Nuvectis Pharma, with six insider buys and no sells over the last", "url": "https://www.gurufocus.com/news/8941625/insider-buying-ron-bentsur-acquires-additional-shares-of-nuvectis-pharma-inc-nvct", "source_name": "GuruFocus", "published_at": "2026-07-01T20:10:41", "published_display": "01 Jul 2026 20:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma Insider Bought Shares Worth $916,000, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/nuvectis-pharma-insider-bought-shares-174736492.html", "source_name": "MT Newswires", "published_at": "2026-07-01T17:47:36+00:00", "published_display": "01 Jul 2026 17:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Nuvectis Pharma, Inc. Insider Trading Activity", "summary": "Emerald Hill Ventures SARL SPF, an entity beneficially owned by 10% owner Charles Mosseri Marlio, purchased 50,000 shares of Nuvectis Pharma, Inc. (NVCT) common stock at a weighted average price of $18.32 per share. This open-market transaction increased their indirect holdings t", "url": "https://www.stocktitan.net/sec-filings/NVCT/form-4-nuvectis-pharma-inc-insider-trading-activity-8722a6506c78.html", "source_name": "Stock Titan", "published_at": "2026-07-01T18:10:41", "published_display": "01 Jul 2026 18:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Nuvectis Pharma Inc For: 1 July By Investing.com", "summary": "This article reports on a Form 4 filing for Nuvectis Pharma Inc (NVCT) for transactions made on July 1st. It also includes current financial market data, indices, commodity prices, and other related financial news, with Nuvectis Pharma's stock showing a 6.14% increase.", "url": "https://ca.investing.com/news/stock-market-news/form-4-nuvectis-pharma-inc-for-1-july-93CH-4716747", "source_name": "Investing.com Canada", "published_at": "2026-07-01T18:10:41", "published_display": "01 Jul 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Raises $100M for Oncology Pivot", "summary": "Nuvectis Pharma, Inc. has raised $100 million through an underwritten public offering to fund the development of three clinical-stage programs acquired from Haisco Pharmaceutical Group. This financing supports a strategic shift to include complement-mediated rare diseases and onc", "url": "https://allsci.com/press-release/nuvectis-replenishes-coffers-after-haisco-deal-with-usd-100m-public-offering/", "source_name": "AllSci", "published_at": "2026-07-01T14:11:35", "published_display": "01 Jul 2026 14:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Makes Nuvectis Pharma, Inc. (NVCT) a Strong Momentum Stock: Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNSWhEQzBMdVJyd1NRdkVVZ3FqYjc4dVNLX0d3S29GMHdwQ21JV2xOck5VSUQtRkZENTNoMzlHZ0xjSlh5OEg4VnVUalhydk1zMmFyTVM2d3BnRmJZUHNyZEEyQnJIVVRzUFhMX1F1endLaVVBWGd3bzI2dDBMQXBraXRNd01kR2o3SWMtMzVPTmc4M3Bod3NmQUFUSQ?oc=5", "source_name": "Market source", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma (NASDAQ: NVCT) cuts and suspends $5M ATM share sales", "summary": "Nuvectis Pharma (NVCT) has reduced the available amount for sales under its \"at-the-market\" equity program with Leerink Partners to $5 million and concurrently suspended the use of the current Sales Agreement Prospectus. The company will not sell shares under this agreement until", "url": "https://www.stocktitan.net/sec-filings/NVCT/8-k-nuvectis-pharma-inc-reports-material-event-f0a12927e0e8.html", "source_name": "Stock Titan", "published_at": "2026-07-01T06:41:24", "published_display": "01 Jul 2026 06:41", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock", "summary": "Nuvectis Pharma, Inc. (Nasdaq: NVCT) announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at $20.00 per share, aiming for gross proceeds of $100 million. The company also granted underwriters a 30-day option to purchase up to an additio", "url": "https://investingnews.com/nuvectis-pharma-announces-pricing-of-100-million-public-offering-of-common-stock/", "source_name": "Investing News Network", "published_at": "2026-07-01T04:40:39", "published_display": "01 Jul 2026 04:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma (NASDAQ: NVCT) to raise $100M in stock sale", "summary": "Nuvectis Pharma announced a firm commitment public offering of 5,000,000 shares of common stock at $20.00 per share, aiming to raise $100 million in gross proceeds. Underwriters have an option to purchase an additional 750,000 shares, potentially increasing net proceeds to $107 m", "url": "https://www.stocktitan.net/sec-filings/NVCT/8-k-nuvectis-pharma-inc-reports-material-event-be803276ce70.html", "source_name": "Stock Titan", "published_at": "2026-07-01T04:09:11", "published_display": "01 Jul 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma Sets 5M-Share, $20 Offering; ~$93M Net, Cantor Fitzgerald Underwriter", "summary": "Nuvectis Pharma has entered into an underwriting agreement with Cantor Fitzgerald for a public offering of 5,000,000 shares of common stock at $20.00 per share. The offering is expected to close on July 1, 2026, and generate approximately $93 million in net proceeds, or about $10", "url": "https://www.tradingview.com/news/tradingview:68b52c684267c:0-nuvectis-pharma-sets-5m-share-20-offering-93m-net-cantor-fitzgerald-underwriter/", "source_name": "TradingView", "published_at": "2026-06-30T21:09:11", "published_display": "30 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock", "summary": "Nuvectis Pharma has announced the pricing of its public offering of 4,000,000 shares of its common stock at $25.00 per share, aiming to raise $100 million before deductions. The offering includes a 30-day option for underwriters to purchase an additional 600,000 shares. The commo", "url": "https://www.moomoo.com/news/post/72224868/press-release-nuvectis-pharma-announces-pricing-of-100-million-public", "source_name": "Moomoo", "published_at": "2026-06-30T18:11:51", "published_display": "30 Jun 2026 18:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma Prices $100 Million Underwritten Public Offering of Common Stock", "summary": "Nuvectis Pharma has announced the pricing of a public offering of 5 million shares of common stock at $20.00 per share, aiming to raise $100 million. The funds are intended to advance the development of its product candidates NXP100, NXP200, and NXP900, alongside hiring and gener", "url": "https://www.quiverquant.com/news/Nuvectis+Pharma+Prices+%24100+Million+Underwritten+Public+Offering+of+Common+Stock", "source_name": "Quiver Quantitative", "published_at": "2026-06-30T14:40:00", "published_display": "30 Jun 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma Prices $100 Million Secondary Stock Offering; Shares Down Pre-Bell", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/nuvectis-pharma-prices-100-million-080246836.html", "source_name": "MT Newswires", "published_at": "2026-06-30T08:02:46+00:00", "published_display": "30 Jun 2026 08:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma's $100 Million Offering: Dilution at a Discount Amidst Pipeline Hopes", "summary": "Nuvectis Pharma recently completed a $100 million public offering at $20.00 per share, significantly diluting existing shareholders but providing critical funding for its oncology and immune complement pipeline. Despite the discount, the stock trades higher at $28.53, reflecting ", "url": "https://www.kavout.com/market-lens/nuvectis-pharma-s-100-million-offering-dilution-at-a-discount-amidst-pipeline-hopes", "source_name": "Kavout | AI", "published_at": "2026-06-30T08:40:34", "published_display": "30 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma shares slide after pricing $100 million discounted stock offering (NVCT)", "summary": "Nuvectis Pharma's shares dropped 25% in premarket trading after the company priced a $100 million public offering at $20.00 per share, a 30% discount from the previous day's closing price of $28.53. The offering involves 5,000,000 shares of common stock, and the underwriters have", "url": "https://finance.yahoo.com/markets/stocks/articles/nuvectis-pharma-shares-slide-pricing-123608598.html", "source_name": "Market source", "published_at": "2026-06-30T08:36:00", "published_display": "30 Jun 2026 08:36", "sentiment": "negative", "sentiment_pct": 27, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma Prices $100 Million Underwritten Public Offering of Common Stock | NVCT Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQdjV4XzlkQzd6T3R4MjhDaVAtWW9oYXQ1REswaDBmOEk5UElCd1RubGNqS1Rhek01NjFJVFF6LWV4d3hvVnVWYU1raDNlcG5LdnZDbnl2NWdtSjRkVmpOUzE5WjQ0Vnc3bk9YRGk2RWdmeGlUVHRqM0J3Y1l0ODdQMWZLOE1yTk9HQmM3eEp1Sm95anBoNWdVLUEzWTV3WDZrU0dQbWEzOXFVRFBzb3ZXMV82eWd4dw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma stock tumbles 25% on discounted offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPZXIyR0ZNeTZuRTdwUTl1Q3lzbEpBX0Vjekt6dnphNkhUR0lzUGE4YlV5OWFSVkI2aWZOa1owbndCT3R1aWlzZXNYRWdsQW8xaGhIVTJUWGR2VTRXM2VSSlhHVExyV3VRX2s5Szk0ajJPMjlieUZvZW1aT1luNk1YQmFNUHF6UGN4MFhXc2RHNTlRRmRWM0NtWmw2NEVESllTczl5TFFOV09sTlU4MXN4TG1Xb2l3UXlw?oc=5", "source_name": "Investing.com", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma Announces Proposed Public Offering of Common Stock", "summary": "Nuvectis Pharma, Inc. (Nasdaq: NVCT) announced the commencement of an underwritten public offering of its common stock, with plans to grant underwriters a 30-day option to purchase an additional 15% of shares. The company intends to use the net proceeds to advance the development", "url": "https://www.globenewswire.com/de/news-release/2026/06/29/3319274/0/en/Nuvectis-Pharma-Announces-Proposed-Public-Offering-of-Common-Stock.html", "source_name": "GlobeNewswire", "published_at": "2026-06-30T04:40:39", "published_display": "30 Jun 2026 04:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma Suspends Equity Offering Program Under Agreement", "summary": "Nuvectis Pharma (NVCT) has announced the suspension of its equity offering program with Leerink Partners LLC. Initially established in May 2025 to allow for periodic sales of common stock, the company decided on June 29, 2026, to reduce the offering size to $5 million and halt fu", "url": "https://www.tipranks.com/news/company-announcements/nuvectis-pharma-suspends-equity-offering-program-under-agreement", "source_name": "TipRanks", "published_at": "2026-06-30T04:10:41", "published_display": "30 Jun 2026 04:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma prices $100 million public offering at $20/share By Investing.com", "summary": "Nuvectis Pharma announced the pricing of a $100 million underwritten public offering of 5,000,000 shares of common stock at $20.00 per share. The company plans to use the net proceeds to advance development programs for NXP100, NXP200, and NXP900, hire additional personnel, and c", "url": "https://ng.investing.com/news/stock-market-news/nuvectis-pharma-prices-100-million-public-offering-at-20share-93CH-2579195", "source_name": "Investing.com Nigeria", "published_at": "2026-06-30T02:40:34", "published_display": "30 Jun 2026 02:40", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis locks in $100M from 5 million-share stock sale", "summary": "Nuvectis Pharma announced the pricing of an underwritten public offering of 5,000,000 common shares at $20.00 per share, aiming to raise $100 million in gross proceeds. The offering includes a 30-day option for underwriters to purchase an additional 750,000 shares. Proceeds will ", "url": "https://www.stocktitan.net/news/NVCT/nuvectis-pharma-announces-pricing-of-100-million-public-offering-of-wqdck3ffcwjz.html", "source_name": "Stock Titan", "published_at": "2026-06-30T02:39:37", "published_display": "30 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma Launches Proposed Public Stock Offering", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/nuvectis-pharma-launches-proposed-public-201807944.html", "source_name": "MT Newswires", "published_at": "2026-06-29T20:18:07+00:00", "published_display": "29 Jun 2026 20:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma Commences Public Stock Offering", "summary": "Nuvectis Pharma (Nasdaq: NVCT) announced an underwritten public offering of common stock to raise capital for the development of its NXP100, NXP200, and NXP900 programs, hiring, and general corporate purposes. This equity financing, with Cantor acting as sole book runner, may lea", "url": "https://www.stocktitan.net/news/NVCT/nuvectis-pharma-announces-proposed-public-offering-of-common-7znz1r0ckzsj.html", "source_name": "Stock Titan", "published_at": "2026-06-29T19:39:37", "published_display": "29 Jun 2026 19:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma seeks fresh capital for cancer and immune programs", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOWDVIQTZtVTJtV2diakpubkJwQldLbVpJWVNJVEpaX0N6OUp1OFlYdTIycmZETWhxOXZRczZWRHNYaE9vSEo3RlA3YmNuUW5BbUU0dWtXVWRMMlFFem1WMlFnZ0s0RG8wRlFmMkNkUFl2SXdyU3VscWctSEZub05PcFF2UkdVTEdIaG82RzJfbGpBM2p0YklCNV9pU3F3YjFPSnRiOTlHRHBld2lGRXBTaFVEZFp1UQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma Up 97%, Insider Buyers Are Up 344%", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma, Inc. Actuals & Estimates (NASDAQ:NVCT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPT01JMGVvMUZsaHUxc3BMN1VRaVB4bnpYd0M3U3NYZGpTYmNmYmFmWmhqRGVYbzgzRG4zdFZSRFJfQ3lXeTRKZ2VueVJiWkxxeFp2ZFUtTEFZMDE0R1RJdlp2bVZCVE5Rd05UcW82emhFRm9aTzlxQ2l0WnMyTnF2aDVDdDhVUQ?oc=5", "source_name": "TradingView", "published_at": "2026-06-26T09:41:19+00:00", "published_display": "26 Jun 2026 09:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Makes Nuvectis Pharma (NVCT) a New Buy Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQVjdtTGREVnhzXzhjZnBMYnBiQlpoUzkxdEV5VzdpMUVReC04RzJMd0hLVlA5d2VockFndFpmYm9UOXFNZTdkVkpRT0pPVENoS2tIMXpJWXdHOXotNVoxRUZpaU9nNEYxd2xzOWFJLU1RbndUQjZEdy1MZThUd2pIdWtnX1BkMF92VFFNOG4wZlFxMFBKWFRxLVRNQQ?oc=5", "source_name": "Market source", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma Jumps 20% To 52-Week High \u2014 Here's Why NVCT Stock Is Trending", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOck9DM1UwVjc5NWNEZGdkcU1TcjNuWWhWRXE1dXJQejFTckgydUtnUHhkRGVTMmxvdjUxQXlSdFl3eU5Ec21PUkdfcGpST0dSN0Q0alI4YXhVdndyNUVnZjA0eVhpUkNnSXVLS19WM2RFbDdLLXdRTnJCQ0tYdW5BVG9na281b3dQaVlaT0NhMXR3SGNZRVVoMGRtSzZZNTVjY0M0RUNtS254WE9pTUJsZVF3Q2VVRzJSby01RWxvdi13WkE?oc=5", "source_name": "Sahm", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Companies Like Nuvectis Pharma (NASDAQ:NVCT) Are In A Position To Invest In Growth", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Here's Why We're Not Too Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxOTVlVdkxwYWtVeEN6VFN1WHI3NnRsaUE2Uzl0ZlVaN2NJOGZST2FjeTZFcC00Ty04NF8yeEV6TlFxNXRWRlQzcXV2MFdFNzdhSjlZWlBrNHdZV2tJYVdHOWl6NHdhV0NXUXU2M1RORnBRZ040VjNQMDN4U3NsLXFVWVZZUk9oNm1ET0VIMnNka0E?oc=5", "source_name": "Market source", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma (NVCT) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE1yQWRjUTlSeWh5dEk5cE4zNFB0dmstUEctYV9JcXJhMEk4ZGZOVm5wS3hibGxvcEdOVk9aakU2XzM4aXBxWnlKSXo1Rll3Z3ZqR21wLThxakFVQQ?oc=5", "source_name": "MarketBeat", "published_at": "2022-02-05T05:50:14+00:00", "published_display": "05 Feb 2022 05:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data", "summary": "Nuvectis Pharma (NASDAQ: NVCT) has secured worldwide rights outside China for NXP100, a once-daily oral therapy for paroxysmal nocturnal hemoglobinuria (PNH), following a licensing deal with Haisco Pharmaceutical Group. NXP100 showed strong positive Phase 3 data, outperforming th", "url": "https://www.cantechletter.com/newswires/streetwatch-nuvectis-pharma-eyes-9-8-billion-oral-pnh-market-with-late-stage-nxp100-backed-by-strong-positive-phase-3-data/", "source_name": "Cantech Letter", "published_at": "2026-07-14T15:43:45", "published_display": "14 Jul 2026 15:43", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Wire: StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data", "summary": "Nuvectis Pharma (NASDAQ: NVCT) recently acquired worldwide rights outside China for NXP100, a promising once-daily oral therapy for paroxysmal nocturnal hemoglobinuria (PNH), following a licensing deal with Haisco Pharmaceutical Group. This acquisition, supported by strong Phase ", "url": "https://www.finanznachrichten.de/nachrichten-2026-07/69024121-wall-street-wire-streetwatch-nuvectis-pharma-eyes-dollar-9-8-billion-oral-pnh-market-with-late-stage-nxp100-backed-by-strong-positive-phase-3-data-296.htm", "source_name": "FinanzNachrichten.de", "published_at": "2026-07-14T14:42:58", "published_display": "14 Jul 2026 14:42", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How (NVCT) Movements Inform Risk Allocation Models", "summary": "This article analyzes Nuvectis Pharma Inc. (NASDAQ: NVCT) using AI models to provide insights into its market movements and inform risk allocation. It highlights weak near-term sentiment but strong mid and long-term signals, offering three distinct trading strategies tailored to ", "url": "https://news.stocktradersdaily.com/news_release/9/How_NVCT_Movements_Inform_Risk_Allocation_Models_071326083802_1783989482.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-13T20:41:32", "published_display": "13 Jul 2026 20:41", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Billion-Dollar Pill: With NXP100, Nuvectis Pharma Just Staked Its Claim in the New Biotech Gold Rush", "summary": "Nuvectis Pharma recently acquired worldwide rights outside China for NXP100, a once-daily pill for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. This acquisition, along with an oncology drug NXP200, signifies the company's shift from a single-drug oncology foc", "url": "https://www.tradingview.com/news/financewire:4bad5ea45094b:0-the-billion-dollar-pill-with-nxp100-nuvectis-pharma-just-staked-its-claim-in-the-new-biotech-gold-rush/", "source_name": "TradingView", "published_at": "2026-07-09T19:11:42", "published_display": "09 Jul 2026 19:11", "sentiment": "positive", "sentiment_pct": 86, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma Inc (NVCT) News, Articles, Events & Latest Updates", "summary": "This article provides recent news and updates for Nuvectis Pharma Inc (NVCT), including analyst ratings and price targets suggesting significant upside potential. It highlights the company's recent earnings beat, increased holdings by Iridian Asset Management, and a stock jump fo", "url": "https://stocktwits.com/symbol/NVCT/news", "source_name": "Stocktwits", "published_at": "2026-07-09T08:11:18", "published_display": "09 Jul 2026 08:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQZkpQM0t1Zkdta2V0d2pleXIxcXlMYlpQQm5oX1VZa3RxcnNmTTM2RDBsVTQwMl9IY3pyUVFlclpLaGxRczlmRWMwN3d3aUxpZnFlbGpmR2ZKX3RzbGZ1MGJNQmd3YVkwMWdBRnc5a1hjRGMxSmdxb3NueXYyX2VTdjFwR2kwdTNkM2ZGMUw4dzFVWGl5Q1VR?oc=5", "source_name": "Market source", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma (Nasdaq:NVCT) - Stock Analysis", "summary": "Nuvectis Pharma (NVCT) is a clinical-stage biopharmaceutical company focused on oncology, currently developing precision medicines NXP900 and NXP800. The company has a market capitalization of US$605.3m, but faces significant risks including revenue less than US$1m, unprofitabili", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nvct/nuvectis-pharma", "source_name": "Simply Wall Street", "published_at": "2026-07-07T19:42:38", "published_display": "07 Jul 2026 19:42", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma Price Target Raised to $33.00/Share From $20.00 by Roth Capital", "summary": "Roth Capital has increased its price target for Nuvectis Pharma (NVCT) to $33.00 per share, up from the previous $20.00. This revision suggests a significantly more optimistic outlook on the company's future stock performance.", "url": "https://www.moomoo.com/news/post/72513900/nuvectis-pharma-price-target-raised-to-33-00-share-from", "source_name": "Moomoo", "published_at": "2026-07-06T18:41:13", "published_display": "06 Jul 2026 18:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roth Capital raises Nuvectis target to $33", "summary": "Roth Capital analyst Jonathan Aschoff maintained a Buy rating on Nuvectis Pharma and increased the price target from $20 to $33. This adjustment follows Nuvectis's announcement of a $100 million public offering of 5,000,000 shares at $20.00 each, with the proceeds intended to adv", "url": "https://scanx.trade/stock-market-news/ipo/nuvectis-pharma-commences-underwritten-public-offering-of-common-stock/44309255", "source_name": "scanx.trade", "published_at": "2026-07-06T16:11:51", "published_display": "06 Jul 2026 16:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma (NVCT) CEO Ron Bentsur buys $250,000 in shares", "summary": "Nuvectis Pharma's Chairman and CEO, Ron Bentsur, purchased 12,500 shares of common stock at $20.00 per share, totaling $250,000. This open-market purchase was part of a public offering announced on June 29, 2026. Following this transaction, Bentsur directly owns 3,688,424 shares ", "url": "https://www.stocktitan.net/sec-filings/NVCT/form-4-nuvectis-pharma-inc-insider-trading-activity-c8daabf9cc9e.html", "source_name": "Stock Titan", "published_at": "2026-07-02T05:40:07", "published_display": "02 Jul 2026 05:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma Announces Major Public Equity Offering", "summary": "Nuvectis Pharma (NVCT) announced a firm-commitment public offering of 5,000,000 common shares at $20.00 each through Cantor Fitzgerald, with an option for underwriters to purchase an additional 750,000 shares. This offering is expected to raise approximately $93 million in net pr", "url": "https://www.theglobeandmail.com/investing/markets/stocks/NVCT-Q/pressreleases/3086810/nuvectis-pharma-announces-major-public-equity-offering/", "source_name": "The Globe and Mail", "published_at": "2026-07-02T05:10:08", "published_display": "02 Jul 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma 10% owner Mosseri buys $916k in shares", "summary": "Marlio Charles Mosseri, a 10% owner of Nuvectis Pharma (NASDAQ:NVCT), acquired 50,000 shares worth $916,000 on June 30, 2026, at an average price of $18.32 per share. This insider purchase follows a significant stock decline and a $100 million public offering at a 30% discount. D", "url": "https://www.investing.com/news/insider-trading-news/nuvectis-pharma-10-owner-mosseri-buys-916k-in-shares-93CH-4771166", "source_name": "Investing.com", "published_at": "2026-07-02T04:40:40", "published_display": "02 Jul 2026 04:40", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Buying: Ron Bentsur Acquires Additional Shares of Nuvectis Pharma Inc (NVCT)", "summary": "Ron Bentsur, Chairman & CEO of Nuvectis Pharma Inc (NVCT), recently purchased 12,500 shares of the company, bringing his total ownership to 3,688,424 shares. This transaction is part of a trend of insider buying at Nuvectis Pharma, with six insider buys and no sells over the last", "url": "https://www.gurufocus.com/news/8941625/insider-buying-ron-bentsur-acquires-additional-shares-of-nuvectis-pharma-inc-nvct", "source_name": "GuruFocus", "published_at": "2026-07-01T20:10:41", "published_display": "01 Jul 2026 20:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma Insider Bought Shares Worth $916,000, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/nuvectis-pharma-insider-bought-shares-174736492.html", "source_name": "MT Newswires", "published_at": "2026-07-01T17:47:36+00:00", "published_display": "01 Jul 2026 17:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Nuvectis Pharma, Inc. Insider Trading Activity", "summary": "Emerald Hill Ventures SARL SPF, an entity beneficially owned by 10% owner Charles Mosseri Marlio, purchased 50,000 shares of Nuvectis Pharma, Inc. (NVCT) common stock at a weighted average price of $18.32 per share. This open-market transaction increased their indirect holdings t", "url": "https://www.stocktitan.net/sec-filings/NVCT/form-4-nuvectis-pharma-inc-insider-trading-activity-8722a6506c78.html", "source_name": "Stock Titan", "published_at": "2026-07-01T18:10:41", "published_display": "01 Jul 2026 18:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Nuvectis Pharma Inc For: 1 July By Investing.com", "summary": "This article reports on a Form 4 filing for Nuvectis Pharma Inc (NVCT) for transactions made on July 1st. It also includes current financial market data, indices, commodity prices, and other related financial news, with Nuvectis Pharma's stock showing a 6.14% increase.", "url": "https://ca.investing.com/news/stock-market-news/form-4-nuvectis-pharma-inc-for-1-july-93CH-4716747", "source_name": "Investing.com Canada", "published_at": "2026-07-01T18:10:41", "published_display": "01 Jul 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Raises $100M for Oncology Pivot", "summary": "Nuvectis Pharma, Inc. has raised $100 million through an underwritten public offering to fund the development of three clinical-stage programs acquired from Haisco Pharmaceutical Group. This financing supports a strategic shift to include complement-mediated rare diseases and onc", "url": "https://allsci.com/press-release/nuvectis-replenishes-coffers-after-haisco-deal-with-usd-100m-public-offering/", "source_name": "AllSci", "published_at": "2026-07-01T14:11:35", "published_display": "01 Jul 2026 14:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Makes Nuvectis Pharma, Inc. (NVCT) a Strong Momentum Stock: Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNSWhEQzBMdVJyd1NRdkVVZ3FqYjc4dVNLX0d3S29GMHdwQ21JV2xOck5VSUQtRkZENTNoMzlHZ0xjSlh5OEg4VnVUalhydk1zMmFyTVM2d3BnRmJZUHNyZEEyQnJIVVRzUFhMX1F1endLaVVBWGd3bzI2dDBMQXBraXRNd01kR2o3SWMtMzVPTmc4M3Bod3NmQUFUSQ?oc=5", "source_name": "Market source", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma (NASDAQ: NVCT) cuts and suspends $5M ATM share sales", "summary": "Nuvectis Pharma (NVCT) has reduced the available amount for sales under its \"at-the-market\" equity program with Leerink Partners to $5 million and concurrently suspended the use of the current Sales Agreement Prospectus. The company will not sell shares under this agreement until", "url": "https://www.stocktitan.net/sec-filings/NVCT/8-k-nuvectis-pharma-inc-reports-material-event-f0a12927e0e8.html", "source_name": "Stock Titan", "published_at": "2026-07-01T06:41:24", "published_display": "01 Jul 2026 06:41", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock", "summary": "Nuvectis Pharma, Inc. (Nasdaq: NVCT) announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at $20.00 per share, aiming for gross proceeds of $100 million. The company also granted underwriters a 30-day option to purchase up to an additio", "url": "https://investingnews.com/nuvectis-pharma-announces-pricing-of-100-million-public-offering-of-common-stock/", "source_name": "Investing News Network", "published_at": "2026-07-01T04:40:39", "published_display": "01 Jul 2026 04:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma (NASDAQ: NVCT) to raise $100M in stock sale", "summary": "Nuvectis Pharma announced a firm commitment public offering of 5,000,000 shares of common stock at $20.00 per share, aiming to raise $100 million in gross proceeds. Underwriters have an option to purchase an additional 750,000 shares, potentially increasing net proceeds to $107 m", "url": "https://www.stocktitan.net/sec-filings/NVCT/8-k-nuvectis-pharma-inc-reports-material-event-be803276ce70.html", "source_name": "Stock Titan", "published_at": "2026-07-01T04:09:11", "published_display": "01 Jul 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma Sets 5M-Share, $20 Offering; ~$93M Net, Cantor Fitzgerald Underwriter", "summary": "Nuvectis Pharma has entered into an underwriting agreement with Cantor Fitzgerald for a public offering of 5,000,000 shares of common stock at $20.00 per share. The offering is expected to close on July 1, 2026, and generate approximately $93 million in net proceeds, or about $10", "url": "https://www.tradingview.com/news/tradingview:68b52c684267c:0-nuvectis-pharma-sets-5m-share-20-offering-93m-net-cantor-fitzgerald-underwriter/", "source_name": "TradingView", "published_at": "2026-06-30T21:09:11", "published_display": "30 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock", "summary": "Nuvectis Pharma has announced the pricing of its public offering of 4,000,000 shares of its common stock at $25.00 per share, aiming to raise $100 million before deductions. The offering includes a 30-day option for underwriters to purchase an additional 600,000 shares. The commo", "url": "https://www.moomoo.com/news/post/72224868/press-release-nuvectis-pharma-announces-pricing-of-100-million-public", "source_name": "Moomoo", "published_at": "2026-06-30T18:11:51", "published_display": "30 Jun 2026 18:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma Prices $100 Million Underwritten Public Offering of Common Stock", "summary": "Nuvectis Pharma has announced the pricing of a public offering of 5 million shares of common stock at $20.00 per share, aiming to raise $100 million. The funds are intended to advance the development of its product candidates NXP100, NXP200, and NXP900, alongside hiring and gener", "url": "https://www.quiverquant.com/news/Nuvectis+Pharma+Prices+%24100+Million+Underwritten+Public+Offering+of+Common+Stock", "source_name": "Quiver Quantitative", "published_at": "2026-06-30T14:40:00", "published_display": "30 Jun 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma Prices $100 Million Secondary Stock Offering; Shares Down Pre-Bell", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/nuvectis-pharma-prices-100-million-080246836.html", "source_name": "MT Newswires", "published_at": "2026-06-30T08:02:46+00:00", "published_display": "30 Jun 2026 08:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma's $100 Million Offering: Dilution at a Discount Amidst Pipeline Hopes", "summary": "Nuvectis Pharma recently completed a $100 million public offering at $20.00 per share, significantly diluting existing shareholders but providing critical funding for its oncology and immune complement pipeline. Despite the discount, the stock trades higher at $28.53, reflecting ", "url": "https://www.kavout.com/market-lens/nuvectis-pharma-s-100-million-offering-dilution-at-a-discount-amidst-pipeline-hopes", "source_name": "Kavout | AI", "published_at": "2026-06-30T08:40:34", "published_display": "30 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma shares slide after pricing $100 million discounted stock offering (NVCT)", "summary": "Nuvectis Pharma's shares dropped 25% in premarket trading after the company priced a $100 million public offering at $20.00 per share, a 30% discount from the previous day's closing price of $28.53. The offering involves 5,000,000 shares of common stock, and the underwriters have", "url": "https://finance.yahoo.com/markets/stocks/articles/nuvectis-pharma-shares-slide-pricing-123608598.html", "source_name": "Market source", "published_at": "2026-06-30T08:36:00", "published_display": "30 Jun 2026 08:36", "sentiment": "negative", "sentiment_pct": 27, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma Prices $100 Million Underwritten Public Offering of Common Stock | NVCT Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQdjV4XzlkQzd6T3R4MjhDaVAtWW9oYXQ1REswaDBmOEk5UElCd1RubGNqS1Rhek01NjFJVFF6LWV4d3hvVnVWYU1raDNlcG5LdnZDbnl2NWdtSjRkVmpOUzE5WjQ0Vnc3bk9YRGk2RWdmeGlUVHRqM0J3Y1l0ODdQMWZLOE1yTk9HQmM3eEp1Sm95anBoNWdVLUEzWTV3WDZrU0dQbWEzOXFVRFBzb3ZXMV82eWd4dw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma stock tumbles 25% on discounted offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPZXIyR0ZNeTZuRTdwUTl1Q3lzbEpBX0Vjekt6dnphNkhUR0lzUGE4YlV5OWFSVkI2aWZOa1owbndCT3R1aWlzZXNYRWdsQW8xaGhIVTJUWGR2VTRXM2VSSlhHVExyV3VRX2s5Szk0ajJPMjlieUZvZW1aT1luNk1YQmFNUHF6UGN4MFhXc2RHNTlRRmRWM0NtWmw2NEVESllTczl5TFFOV09sTlU4MXN4TG1Xb2l3UXlw?oc=5", "source_name": "Investing.com", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma Announces Proposed Public Offering of Common Stock", "summary": "Nuvectis Pharma, Inc. (Nasdaq: NVCT) announced the commencement of an underwritten public offering of its common stock, with plans to grant underwriters a 30-day option to purchase an additional 15% of shares. The company intends to use the net proceeds to advance the development", "url": "https://www.globenewswire.com/de/news-release/2026/06/29/3319274/0/en/Nuvectis-Pharma-Announces-Proposed-Public-Offering-of-Common-Stock.html", "source_name": "GlobeNewswire", "published_at": "2026-06-30T04:40:39", "published_display": "30 Jun 2026 04:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma Suspends Equity Offering Program Under Agreement", "summary": "Nuvectis Pharma (NVCT) has announced the suspension of its equity offering program with Leerink Partners LLC. Initially established in May 2025 to allow for periodic sales of common stock, the company decided on June 29, 2026, to reduce the offering size to $5 million and halt fu", "url": "https://www.tipranks.com/news/company-announcements/nuvectis-pharma-suspends-equity-offering-program-under-agreement", "source_name": "TipRanks", "published_at": "2026-06-30T04:10:41", "published_display": "30 Jun 2026 04:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma prices $100 million public offering at $20/share By Investing.com", "summary": "Nuvectis Pharma announced the pricing of a $100 million underwritten public offering of 5,000,000 shares of common stock at $20.00 per share. The company plans to use the net proceeds to advance development programs for NXP100, NXP200, and NXP900, hire additional personnel, and c", "url": "https://ng.investing.com/news/stock-market-news/nuvectis-pharma-prices-100-million-public-offering-at-20share-93CH-2579195", "source_name": "Investing.com Nigeria", "published_at": "2026-06-30T02:40:34", "published_display": "30 Jun 2026 02:40", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis locks in $100M from 5 million-share stock sale", "summary": "Nuvectis Pharma announced the pricing of an underwritten public offering of 5,000,000 common shares at $20.00 per share, aiming to raise $100 million in gross proceeds. The offering includes a 30-day option for underwriters to purchase an additional 750,000 shares. Proceeds will ", "url": "https://www.stocktitan.net/news/NVCT/nuvectis-pharma-announces-pricing-of-100-million-public-offering-of-wqdck3ffcwjz.html", "source_name": "Stock Titan", "published_at": "2026-06-30T02:39:37", "published_display": "30 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma Launches Proposed Public Stock Offering", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/nuvectis-pharma-launches-proposed-public-201807944.html", "source_name": "MT Newswires", "published_at": "2026-06-29T20:18:07+00:00", "published_display": "29 Jun 2026 20:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma Commences Public Stock Offering", "summary": "Nuvectis Pharma (Nasdaq: NVCT) announced an underwritten public offering of common stock to raise capital for the development of its NXP100, NXP200, and NXP900 programs, hiring, and general corporate purposes. This equity financing, with Cantor acting as sole book runner, may lea", "url": "https://www.stocktitan.net/news/NVCT/nuvectis-pharma-announces-proposed-public-offering-of-common-7znz1r0ckzsj.html", "source_name": "Stock Titan", "published_at": "2026-06-29T19:39:37", "published_display": "29 Jun 2026 19:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma seeks fresh capital for cancer and immune programs", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOWDVIQTZtVTJtV2diakpubkJwQldLbVpJWVNJVEpaX0N6OUp1OFlYdTIycmZETWhxOXZRczZWRHNYaE9vSEo3RlA3YmNuUW5BbUU0dWtXVWRMMlFFem1WMlFnZ0s0RG8wRlFmMkNkUFl2SXdyU3VscWctSEZub05PcFF2UkdVTEdIaG82RzJfbGpBM2p0YklCNV9pU3F3YjFPSnRiOTlHRHBld2lGRXBTaFVEZFp1UQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma Up 97%, Insider Buyers Are Up 344%", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma, Inc. Actuals & Estimates (NASDAQ:NVCT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPT01JMGVvMUZsaHUxc3BMN1VRaVB4bnpYd0M3U3NYZGpTYmNmYmFmWmhqRGVYbzgzRG4zdFZSRFJfQ3lXeTRKZ2VueVJiWkxxeFp2ZFUtTEFZMDE0R1RJdlp2bVZCVE5Rd05UcW82emhFRm9aTzlxQ2l0WnMyTnF2aDVDdDhVUQ?oc=5", "source_name": "TradingView", "published_at": "2026-06-26T09:41:19+00:00", "published_display": "26 Jun 2026 09:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Makes Nuvectis Pharma (NVCT) a New Buy Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQVjdtTGREVnhzXzhjZnBMYnBiQlpoUzkxdEV5VzdpMUVReC04RzJMd0hLVlA5d2VockFndFpmYm9UOXFNZTdkVkpRT0pPVENoS2tIMXpJWXdHOXotNVoxRUZpaU9nNEYxd2xzOWFJLU1RbndUQjZEdy1MZThUd2pIdWtnX1BkMF92VFFNOG4wZlFxMFBKWFRxLVRNQQ?oc=5", "source_name": "Market source", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma Jumps 20% To 52-Week High \u2014 Here's Why NVCT Stock Is Trending", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxOck9DM1UwVjc5NWNEZGdkcU1TcjNuWWhWRXE1dXJQejFTckgydUtnUHhkRGVTMmxvdjUxQXlSdFl3eU5Ec21PUkdfcGpST0dSN0Q0alI4YXhVdndyNUVnZjA0eVhpUkNnSXVLS19WM2RFbDdLLXdRTnJCQ0tYdW5BVG9na281b3dQaVlaT0NhMXR3SGNZRVVoMGRtSzZZNTVjY0M0RUNtS254WE9pTUJsZVF3Q2VVRzJSby01RWxvdi13WkE?oc=5", "source_name": "Sahm", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Companies Like Nuvectis Pharma (NASDAQ:NVCT) Are In A Position To Invest In Growth", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Not Too Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxOTVlVdkxwYWtVeEN6VFN1WHI3NnRsaUE2Uzl0ZlVaN2NJOGZST2FjeTZFcC00Ty04NF8yeEV6TlFxNXRWRlQzcXV2MFdFNzdhSjlZWlBrNHdZV2tJYVdHOWl6NHdhV0NXUXU2M1RORnBRZ040VjNQMDN4U3NsLXFVWVZZUk9oNm1ET0VIMnNka0E?oc=5", "source_name": "Market source", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nuvectis Pharma (NVCT) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE1yQWRjUTlSeWh5dEk5cE4zNFB0dmstUEctYV9JcXJhMEk4ZGZOVm5wS3hibGxvcEdOVk9aakU2XzM4aXBxWnlKSXo1Rll3Z3ZqR21wLThxakFVQQ?oc=5", "source_name": "MarketBeat", "published_at": "2022-02-05T05:50:14+00:00", "published_display": "05 Feb 2022 05:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 89, "total_relevant": 52, "sentiment_summary": {"positive": 19, "negative": 7, "neutral": 26, "score": 56, "total": 52, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 84, "events": [{"event": "general", "label": "Market update", "weight": 18.7, "count": 34}, {"event": "earnings", "label": "Earnings", "weight": 4.81, "count": 11}, {"event": "deals", "label": "Deals and strategy", "weight": 1.65, "count": 3}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 19, "negative_events": 7}, "market_context": {"has_market_context": true, "latest_close": 19.14, "latest_week": "2026-07-17", "one_week_move": 4.3, "four_week_move": 38.5, "twelve_week_move": 115.1, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.413583, "market_dynamics_buy_signal": false, "relative_strength": 96.334052, "fair_value_gap": 125.8, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 38.7288, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+4.3% over one week, +38.5% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 67, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 11}, {"label": "Stock Titan", "count": 7}, {"label": "TradingView", "count": 4}, {"label": "simplywall.st", "count": 4}, {"label": "MT Newswires", "count": 3}, {"label": "Moomoo", "count": 2}, {"label": "Investing.com", "count": 2}, {"label": "Quiver Quantitative", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 43}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 34}, {"label": "Earnings", "count": 11}, {"label": "Deals and strategy", "count": 3}, {"label": "Analyst action", "count": 2}, {"label": "Macro sensitivity", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "84/100 classification confidence."}, {"label": "Company focus", "value": "43", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+4.3% over one week, +38.5% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data"}], "updated_at": "2026-07-22T04:01:48.697272+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}